Metformin × cardiovascular events

TrialDiabetes care2013

Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease.

Jie Hong et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 91 people · 2013

Randomised comparison

Probably reduced cardiovascular events

−46%−70% to −10%

Bigger than 9 in 10 for cardiovascular events

As reported

HR 0.54, 95% CI 0.30–0.90

One number in the abstract

the abstract, start to end

showed an adjusted hazard ratio (HR) of 0.54 (95% CI 0.30-0.90; P = 0.026)

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
HR 0.540.30–0.90
MetforminSulfonylureas & glinidesCardiovascular events

Metformin × cardiovascular eventshelps?mixed

unlikelylikely
0.500.50 without it

Sulfonylureas & glinides × cardiovascular eventshelps?replicated

unlikelylikely
0.960.50 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

158 papers cite itlatest 60 shown

2013
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 23230096